

# **ADVERSE EVENTS OF PIRFENIDONE AND CAUSE OF SUSPENSION IN CLINICAL PRACTICE**

P. Suarez-Artime<sup>1</sup>, I. Zarra-Ferro<sup>1</sup>, M. Rodriguez-Cobos<sup>1</sup>, A. Hermida-Cao<sup>1</sup>, R. García-Ramos<sup>1</sup>, A. Martos-Rosa<sup>2</sup>, C. Gonzalez-Anleo<sup>1</sup>, J. Rojo-Valdes<sup>1</sup>, A. Suarez-Rodriguez<sup>1</sup>, M.J. Lamas-Diaz<sup>1</sup>. <sup>1</sup>Complexo Hospitalario Universitario Santiago de Compostela, Pharmacy, Santiago de Compostela, Spain. <sup>2</sup>Hospital de Poniente- El Ejido- Almería, Pharmacy, El Ejido, Spain.

**PURPOSE** 

In 2011, pirfenidone was the first drug to be approved for the treatment of idiopathic pulmonary fibrosis (IPF) in Europe after reduced decline in percentpredicted forced vital capacity (FVC) in the two phase III trials

### BACKGROUND

- 1. Describe the adverse events of the patients on treatment with pirfenidone in the pharmaceutical consultation
- 2. Describe the time of regimen treatment with pirfenidone and the cause of his suspension if there was
- 3. Compare the results obtained with the published in the clinical trials


MATERIAL AND METHODS


- **Prospective**, descriptive and observational study
- Assess the safety and duration of the treatment with pirfenidone lacksquare
- Patients on treatment with pirfenidone were eligible for the study Main variable is the adverse events notified by the patient during the pharmaceutical interview at the outpatient unit of pharmacy

## RESULTS

- 16 patients (4 women , 12 men)
- Mean age: 72,8 years
- 38 adverse events in 12 (75%) patients
- 4 patients that did not report any adverse event
- The most common adverse events were gastrointestinal disorders (18 events)
- 5 patients (31,5%) needed to discontinued pirfenidone due to adverse events (3 women and 2 men)
- Mean duration patients stop drug: 103,4 days • Reasons to discontinue:
  - Gastrointestinal disorders (60%)

### **Pirfenidone Adverse Reactions**





Adverse reactions found in our study are similar to those of clinical trials

### Women have less tolerance to pirfenidone and need lower dose in maintenance treatment

There is a significant percentage of dropouts due to adverse events